Last reviewed · How we verify
relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation
Approved treatments
- Revuforj · Syndax
Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation patent landscape — cliff calendar, originator estates, attackable patents
- relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation treatment landscape brief
- relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation treatment updates RSS
Frequently asked questions about relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation
What drugs treat relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation?
Tracked treatments include Revuforj.
What is the treatment for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation?
Standard treatment for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation includes Revuforj. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation patent cliff · relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation CI report
- Treatment: Revuforj · Syndax
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing